Clinical Trials on ALK-positive NSCLC

Total 433810 results

Betta Pharmaceuticals Co., Ltd.

Unknown

The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human

ALK-POSITIVE NSCLC

China
Pfizer

Completed

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

ALK-positive NSCLC

Sweden
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC

ALK-positive NSCLC

China
AstraZeneca

No longer available

AZD9291 US Expanded Access Program

EGFR T790M Mutation Positive NSCLC

United States
Arbeitsgemeinschaft medikamentoese Tumortherapie

Recruiting

Lung Cancer Registry

Lung Cancer | NSCLC Stage IV | NSCLC, Stage III | SCLC, Extensive Stage | SCLC, Limited Stage

Austria
Yongchang Zhang

Recruiting

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

HER2 Insertion Mutation Positive Advanced NSCLC

China
AstraZeneca

Completed

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC (IFUM)

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Bulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
Pfizer

Recruiting

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

EGFR Mutation-positive Inoperable or Reccrent NSCLC

Japan
Pfizer

Completed

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC

United States, Canada, Australia, Taiwan, Singapore, Japan, Korea, Republic of, Spain, Belgium, Switzerland, France, Germany, Hong Kong, Italy
Dr Joanne CHIU

Recruiting

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

ALK Gene Rearrangement Positive | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Activating Mutation | Nsclc | ROS1 Gene Rearrangement | ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer

Hong Kong
National Cancer Centre, Singapore
Pfizer

Active, not recruiting

Phase 2 Study of Dacomitinib in NSCLC

NSCLC Stage IV | NSCLC Stage IIIB | Recurrent NSCLC | NSCLC Stage IIIC | EGFR Positive Non-Small Cell Lung Cancer

Korea, Republic of, Hong Kong, Thailand, Singapore, Malaysia
AstraZeneca

Completed

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

T790M Positive NSCLC Patients

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring

Untreated Advanced NSCLC Patients | FISH Identified ALK Fusion Positive or Negative

China
ETOP IBCSG Partners Foundation
GlaxoSmithKline; Development Limited

Recruiting

Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC (RAISE)

SCLC,Extensive Stage | SLFN11-positive

Switzerland, France, Spain, Italy
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

NSCLC | AML | SCLC | Ovarian Carcinoma | Malignant Tumor | ESCC | CRPC | MF

China
Maastricht Radiation Oncology
Academisch Ziekenhuis Maastricht

Terminated

Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation (FDG-PET lung)

NSCLC | Lung Cancer | SCLC

Netherlands
Peking University Cancer Hospital & Institute
Betta Pharmaceuticals Co., Ltd.

Recruiting

Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer (EFLRWR)

NSCLC Stage IV | NSCLC Stage IIIB | ALK Positive

China
Dana-Farber Cancer Institute
Genentech, Inc.

Terminated

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

ALK-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Thyroid Cancer

United States
Pfizer

Terminated

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

ALK or ROS1-positive NSCLC

China
Li Zhang, MD

Recruiting

Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance (ERSGATR)

The Diagnosis Was ALK Positive NSCLC | Second Generation ALK-TKI is Resistant | Efficacy of Ensatinib in This Subset of Patients

China
Shanghai Henlius Biotech

Completed

Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects

NSCLC

China
The Netherlands Cancer Institute

Enrolling by invitation

The Food-effect on Alectinib Pharmacokinetics

NSCLC

Netherlands
Biocartis NV
AstraZeneca

Withdrawn

EGFR_IUO 3.20 Clinical Study Protocol

NSCLC
Centre Oscar Lambret
University Hospital, Lille

Terminated

Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation (CONCORDE)

Nsclc

France
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

To Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Alkotinib Capsules in Healthy Subjects

NSCLC

China
Bio-Thera Solutions

Completed

Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects

NSCLC

New Zealand
Centre Francois Baclesse
GFPC

Recruiting

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018)

ALK Gene Rearrangement Positive | NSCLC Stage IV | NSCLC Stage IIIB | EGFR Gene Mutation | ROS1 Gene Mutation

France
Jiangsu Province Nanjing Brain Hospital

Recruiting

The Dynamic Monitoring of Cerebrospinal Fluid ctDNA

NSCLC

China
TYK Medicines, Inc

Recruiting

Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects

NSCLC

China
Radboud University Medical Center
Pfizer; ImaginAb, Inc.; University Hospital Tuebingen

Not yet recruiting

Immuno-pet iMaging resPonses administeRed Immune checkpoiNt inhibiTor (IMPRINT)

NSCLC

Germany, Netherlands
Beta Pharma, Inc.

Completed

A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711

NSCLC

China
Pfizer

Completed

A Rollover Protocol of Dacomitinib For Patients In Japan

NSCLC

Japan
Tianjin Medical University Cancer Institute and...
Guangzhou Burning Rock Dx Co., Ltd.; AstraZeneca Investment (China) Co., Ltd

Completed

Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing

NSCLC
Xinqiao Hospital of Chongqing

Completed

Clinical Research for the Consistency Analysis of PD-L1 in Cancer Tissue and Plasma Exosome (RadImm01)

NSCLC
Seoul St. Mary's Hospital
Boehringer Ingelheim

Active, not recruiting

Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy

NSCLC

Korea, Republic of
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital; China Medical University Hospital; Tri-Service... and other collaborators

Unknown

Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy

NSCLC

Taiwan
AstraZeneca

Completed

Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study

NSCLC

Sweden, Bulgaria, Mexico, Russian Federation, Turkey, United Kingdom, Philippines, Malaysia, Germany, Hungary, Latvia, Lithuania, Poland, Romania, Netherlands, Norway, Argentina, Australia, Canada, Slovakia, Greece, Taiwan, Thailand, ... and more
Xiaorong Dong

Unknown

The Role of Microbiota on the Development of Lung Cancer

Healthy Subjects | NSCLC Stage IV | NSCLC, Stage III | NSCLC, Stage I | NSCLC, Stage II

China
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Alectinib-induced Endocrine Toxicity (TOSS-ALK)

NSCLC Stage IV

Italy
Spanish Lung Cancer Group

Completed

T790M Mutation Testing in Blood by Different Methodologies

NSCLC Stage IV

Spain
Fox Chase Cancer Center
WindMIL Therapeutics

Withdrawn

Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab

NSCLC | SCLC
Jair Bar, M.D., Ph.D.

Not yet recruiting

Neo-Bio-ADAURA: A Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib

Non-squamous NSCLC
The Netherlands Cancer Institute
AstraZeneca

Unknown

Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment (Induction)

Stage III NSCLC

Netherlands
University Hospital Heidelberg
Roche Pharma AG

Recruiting

Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC (iReP)

NSCLC Stage IIIB | NSCLC Stage II | NSCLC, Stage IIIA

Germany
Shanghai Chest Hospital
The Affiliated Hospital of Qingdao University; Zhejiang University; Anhui Provincial...

Recruiting

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) (AK104IIT018)

NSCLC Stage IV | NSCLC Stage IIIB | NSCLC Stage IIIC

China
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

NSCLC, Stage III | NSCLC, Stage I | NSCLC, Stage II

China
Genentech, Inc.
Flatiron Health, Inc.; Foundation Medicine, Inc.

Completed

Prospective Clinicogenomic Program (PCG)

Non-Small Cell Lung Cancer (NSCLC) | Small-Cell Lung Cancer (SCLC)

United States
Fundación GECP

Active, not recruiting

Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (CUBIK)

NSCLC | Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB

Spain
Peking Union Medical College

Recruiting

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

NSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB | NSCLC, Recurrent

China
EQRx, Inc.

Completed

To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations

NSCLC | Healthy Volunteers | Pharmacokinetics

United States, New Zealand

Clinical Trials on ALK-positive NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations